1 / 8

UK Policy considerations on increasing access to medicines for the poor in developing countries. DEPARTMENT FOR INTERNAT

UK Policy considerations on increasing access to medicines for the poor in developing countries. DEPARTMENT FOR INTERNATIONAL DEVELOPMENT. International Development Targets. Poverty: Reduce by 50% the proportion of people living in extreme poverty by 2015 Health and Health Systems

brilliant
Download Presentation

UK Policy considerations on increasing access to medicines for the poor in developing countries. DEPARTMENT FOR INTERNAT

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. UK Policy considerations on increasing access to medicines for the poor in developing countries.DEPARTMENT FOR INTERNATIONAL DEVELOPMENT

  2. International Development Targets • Poverty: • Reduce by 50% the proportion of people living in extreme poverty by 2015 • Health and Health Systems • Reduce maternal mortality rate by ¾ by 2015 • Reduce infant mortality rate by 2/3 by 2015 • Universal access to reproductive health care through primary health systems no later than 2015 • Disease Specific • 25% reduction in HIV infection among 15-24 year olds in worst affected countries • Malaria, TB: Reduce burden by 50% by 2010

  3. Commitment • To poverty reduction, to health, to access to essential commodities • Large Development Budget • from 0.21 - 0.32% of GDP • total FY 1999 £2.53 billion • Health spend 13% • Health systems development • Increasingly direct support to Poverty Reduction Strategies and Budget Support. • Untied as of 2001 • Leadership in Secretary of State

  4. Other influences • Large effective NGO and advocacy community • Large pharmaceutical industry • Large publicly financed health service (NHS)

  5. Lack of Access to medicines: a key impediment to reducing poverty • Important focus • Addressing through: • Working with other partners internationally to consider approaches • Priminister Initiative through the Cabinet office • Variety of policy measures considered to increase access • End of April

  6. Front runners in terms of impact seem to be • Differential pricing • International fund for HIV/AIDs, TB, Malaria, childhood illnesses… to support: • essential drugs and health commodities • or funds for the purchase of drugs and commodities • Health systems (procurement, delivery, logistics support, quality control, training, drug policy) • Others include: Tax measures R&D, tax measures around donations that meet criteria as set out by WHO

  7. On Differential Pricing • Support from UK government departments (DTI, DOH, DFID, CO, $). • Need: • limit parallel re-importation • at no increased cost to NHS drug bill • considerations for middle income countries • Framework • International support (not just UK, or EC) • Identify DP at what level: country or global? • In country targeting the poor or ”trickle down” • keep it simple • support systems development • procurement, transparent tendering etc.

  8. Mix of Strategies Crucial • What potential and limits of differential pricing • Patents and/or Generics • Those only with large markets • What diseases • HIV/AIDs • TB? • Malaria, Diarrheoal diseases, respiratory infections? • Need for a mix of strategies and dramatic Increase in Scale • Look to leadership from WHO

More Related